Dr. Martin J. Schear, MD
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Chicago College of Medicine and Surgery (1977)
- Years since graduation
- 49
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 70
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1977Medical school: Chicago College of Medicine and Surgery
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
OH license 35-041256S
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Miami Valley Hospital Dayton, OH
- Kettering Health Dayton Dayton, OH
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 70
- Services billed
- 235
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 311 | 81 |
| Established patient office or other outpatient visit, 30-39 minutes | 84 | 40 |
| Blood glucose (sugar) level | 42 | 23 |
| Automated urinalysis test | 38 | 26 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 22 | 22 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 11-20 minutes | 17 | 16 |
| Hemoglobin a1c level | 16 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 90 payments worth $1,809 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $396 |
|---|---|
| AbbVie Inc. | $299 |
| Novo Nordisk Inc | $213 |
| Pfizer Inc. | $155 |
| Cequr Corporation | $143 |
| Dexcom, Inc. | $75.54 |
| Exact Sciences Corporation | $74.03 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) | $60.27 |
| Food and Beverage | $1,809 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $104,548 in research payments for these studies, mostly to the institutions running them.
- A master phase 123 protocol to investigate the safety tolerability and immunogenicity of bivalent BNT162B2 rna based vaccine candidates in healthy children
Pfizer Inc. - A phase 3 protocol to investigate the safety tolerability and immunogenicity of a BNT162B2 LP81ADAPTED vaccine in children 5 through 11 years of age considered at high risk for severe COVID19
Pfizer Inc. - A phase 2 randomized doubleblind trial to evaluate the safety tolerability and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy infants
Pfizer Inc. - Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sanofi US Services Inc. · Recruiting · NCT07190209 - A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age
Novavax Inc - A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.